Clin Infect Dis. 2023 Aug 30:ciad519. doi: 10.1093/cid/ciad519. Online ahead of print.
ABSTRACT
In this cohort study conducted in Hong Kong where both bivalent and monovalent formulations of BNT162b2 were available, there was no significant differences in the mortality or hospitalization between those who received bivalent and monovalent mRNA as second boosters. Bivalent and monovalent mRNA boosters appear equally protective against clinical outcomes.
PMID:37647855 | DOI:10.1093/cid/ciad519